ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5104ometendo-5104Research ArticleСтатьиArticlesОценка использования ксеникала в лечении пациентов с ожирением в условиях амбулаторной практики в г. МосквеOtsenka ispol'zovaniya ksenikala v lechenii patsientov s ozhireniem v usloviyakh ambulatornoy praktiki v g. MoskvePetuninaN A-Tel'novaM E-KononovaL V-KhasanovaE R-20091503200961№1 (2009)1822Copyright © Petunina N.A., Tel'nova M.E., Kononova L.V., Khasanova E.R., 20092009Petunina N.A., Tel'nova M.E., Kononova L.V., Khasanova E.R.Petunina N.A., Tel'nova M.E., Kononova L.V., Khasanova E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5104ReferencesДедов И. И., Мельниченко Г. А. Ожирение. М.: Мед. информ. агентство; М.; 2004; 16-23.Дедов И. И., Мельниченко Г. А. Ожирение. М.: Мед. информ. агентство; М.; 2004; 16-23.Ожирение. (клинические очерки). Под редакцией Барановского А.Ю., Ворохобиной Н.В. Диалект; С-Петербург, 2007 ; 9-20.Ожирение. (клинические очерки). Под редакцией Барановского А.Ю., Ворохобиной Н.В. Диалект; С-Петербург, 2007 ; 9-20.Yanovski S. Z., Yanovski J. A., Obesity. N. Engl. J. Med. 2002; 346:591-602.Yanovski S. Z., Yanovski J. A., Obesity. N. Engl. J. Med. 2002; 346:591-602.Bjorntorp P. Obesity. Lancet 1997; 350:423-426.Bjorntorp P. Obesity. Lancet 1997; 350:423-426.Flegal K. M., Carroll M. D., Kuczmarski R. J., Johnson C. L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J. Obes. Relat. Metabol. Disord. 1998; 22:39-47.Flegal K. M., Carroll M. D., Kuczmarski R. J., Johnson C. L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J. Obes. Relat. Metabol. Disord. 1998; 22:39-47.Tounian P., Aggoun Y., Dubern B. et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 385:1400-1404.Tounian P., Aggoun Y., Dubern B. et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 385:1400-1404.Desideri G., De Simone M., lughetti L. et al. Early activation of vascular endothelial cells and platelets in obese children. J. Clin. Endocrinol. Metabol. 2005; 90(6):3145-3152.Desideri G., De Simone M., lughetti L. et al. Early activation of vascular endothelial cells and platelets in obese children. J. Clin. Endocrinol. Metabol. 2005; 90(6):3145-3152.Kahn В. В., Flier J. S. Obesity and insulin resistance. J. Clin. Invest. 2000; 106:473-481.Kahn В. В., Flier J. S. Obesity and insulin resistance. J. Clin. Invest. 2000; 106:473-481.Aronne L. J., Segal R. K. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes. Res. 2002; 10(l):14S-21S.Aronne L. J., Segal R. K. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes. Res. 2002; 10(l):14S-21S.Bray G. A., Greenway F. L. Current and potential drugs for treatment of obesity. Endocr. Rev. 1999; 20:805-875.Bray G. A., Greenway F. L. Current and potential drugs for treatment of obesity. Endocr. Rev. 1999; 20:805-875.Aronne L. J. Therapeutic options for modifying cardiometabolic risk factors. Am. J. Med. 2007; 120(3, suppl.l):S26-S34.Aronne L. J. Therapeutic options for modifying cardiometabolic risk factors. Am. J. Med. 2007; 120(3, suppl.l):S26-S34.Sjostrom L., Rissanen A., Andersen T. et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352:167-172.Sjostrom L., Rissanen A., Andersen T. et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352:167-172.Pinkston M. M., Poston W. S., Reeves R. S. et al. Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? Eat Weight Disord. 2006; 11(1): e35-e41.Pinkston M. M., Poston W. S., Reeves R. S. et al. Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification? Eat Weight Disord. 2006; 11(1): e35-e41.Richelsen В., Tonstad S., Rossner S. et al. Effect of orlistat on weight regain and cardiovascular risk factors following a verylowenergy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabet. Care 2007; 30(l): 27-32.Richelsen В., Tonstad S., Rossner S. et al. Effect of orlistat on weight regain and cardiovascular risk factors following a verylowenergy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabet. Care 2007; 30(l): 27-32.
The authors declare that there are no conflicts of interest present.